© Reuters. A test tube is seen in front of displayed Biogen logo in this illustration taken, December 1, 2021. REUTERS/Dado Ruvic/Illustration
WASHINGTON (Reuters) – The U.S. Justice Department said on Monday that Biogen Inc (NASDAQ:) had agreed to pay $900 million to resolve allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs, leading to the submission of false Medicare and Medicaid claims.
Be the first to comment